Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
Sep 29, 2020
Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators
-
Sep 28, 2020
New findings to be presented at The North American Menopause Society (NAMS) 2020 Virtual Annual Meeting
-
-
Sep 18, 2020
- Trial Stopped Early Due to Positive Results at Planned Interim Analysis -
-
-
Sep 1, 2020
Recent grants and redirected funding help to respond to the COVID-19 pandemic by improving healthcare infrastructure, training and education in low-income countries
-
Aug 4, 2020
-Tackling everyday challenges in cancer care, apply by September 28, 2020-
-
Jul 23, 2020
Astellas "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas
-
-
Jun 8, 2020
- Study meets primary endpoint demonstrating non-inferiority of roxadustat to darbepoetin in correction and maintenance of hemoglobin levels
-
May 29, 2020
Data simultaneously published in the New England Journal of Medicine and presented during the virtual scientific program of the 2020 ASCO Annual Meeting
-
May 29, 2020
XTANDI is now MHLW-approved for both metastatic hormone-sensitive prostate cancer and castration-resistant prostate cancer in Japan
-
-
May 20, 2020
Submission for the treatment of anemia in adult patients with chronic kidney disease
-
-
-
Feb 19, 2020
- Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -
-
-
Feb 10, 2020
- After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination -
- Findings To Be Presented During an Oral Session at the 2020 Genitourinary Cancers Symposium -
-
Feb 10, 2020
- New Funding will Address Disparities in Mental Health Diagnosis and Treatment for 400,000 People in Need -
-
-
-
Jan 15, 2020
- Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation Primary Focus
-
-
Dec 26, 2019
Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy